Zonisamide vs. Placebo in the Treatment of Alcohol Dependence
|ClinicalTrials.gov Identifier: NCT00595556|
Recruitment Status : Completed
First Posted : January 16, 2008
Results First Posted : October 15, 2010
Last Update Posted : October 15, 2010
|Condition or disease||Intervention/treatment||Phase|
|Alcoholism Alcohol Abuse Alcohol Dependence||Drug: zonisamide Drug: Placebo||Phase 4|
Zonisamide is an antiepileptic medication which has similar clinical and pharmacologic effects to topiramate, a medication that has demonstrated efficacy in a randomized clinical trial for treatment of alcoholism. Because zonisamide is potentially better tolerated and easier to titrate in the outpatient setting than topiramate, it may offer important clinical advantages in the treatment of alcoholism.
This is a small 12-week placebo-controlled pilot study examining tolerability and potential efficacy in anticipation of a larger, placebo-controlled trial of zonisamide for treatment of alcohol dependence. It is a randomized, double-blind trial of zonisamide vs. placebo at flexible dosages of 100-500mg/day in alcoholics receiving ambulatory psychosocial treatment. Participants will take part in six individual Cognitive-Behavioral based therapy sessions, which are focused on learning coping skills. Participants must endorse a goal of either cutting down their drinking to non-hazardous levels, or abstinence.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Zonisamide vs. Placebo in the Treatment of Alcohol Dependence|
|Study Start Date :||July 2006|
|Primary Completion Date :||May 2009|
|Study Completion Date :||May 2009|
flexible dosages of 100-500mg/day
Other Name: Zonegran
Placebo Comparator: B
- Change in Number of Heavy Drinking Days (i.e., 5 or More Drinks Per Day for Men, and 4 or More Per Day for Women)Per Week, by Week [ Time Frame: baseline to the end of 12 weeks in treatment ]This outcome measure represents the change in number of heavy drinking days (i.e., 5 or more drinks per day for men, and 4 or more per day for women)per week, from baseline to the end of week twelve. This was analyzed using weekly measurements over the 12 week study period (thirteen time points, 12 measurements)with a repeated measures analysis (SPSS linear mixed models), by interaction with time (week).
- Weekly Rate of Change in Abstinent Days [ Time Frame: baseline to the end of 12 weeks in treatment ]This outcome measure analyzed the weekly rate of change in number of abstinent days over the twelve weeks of the study from baseline to the end of week twelve. This was analyzed using weekly measurements over the 12 week study period (thirteen time points, 12 measurements)with a repeated measures analysis (SPSS proc mixed), by interaction with time (week).
- Change in Number of Drinks Per Week by Week [ Time Frame: baseline to the end of 12 weeks in treatment ]This outcome measure represents the change in the total number of standard drinks per week (weekly data) from baseline to the end of week twelve. This was analyzed using weekly measurements from baseline to week 12 week of the study period (thirteen time points, 12 measurements)with a repeated measures analysis (SPSS linear mixed models), by interaction with time (week).
- Change in the Urge to Drink Alcohol as Measured by the Alcohol Urge Questionnaire (AUQ) [ Time Frame: baseline to the end of 12 weeks in treatment ]This is the change in measured urge to drink alcohol as measured by the Alcohol Urge Questionnaire (AUQ), measured every 2 weeks from baseline until the last week of the study (over twelve weeks, 7 timepoint measurements of AUQ, 6 calculated changes). It is reported in terms of change per visit (every 2 weeks). AUQ measures a feeling state, and uses a 7 point (1-7)Likert scale for each of 8 items (questions). The lowest urge score is 8 (representing less urge to drink), and the highest would be tabulated as 56 (meaning more urge to drink). Repeated measures SPPS linear mixed models used.
- Change in Gamma-glutamyl Transferase (GGT) Concentration [ Time Frame: 12 weeks (from initiation to end of treatment) ]This outcome measure looks at the change in blood levels of this enzyme assay from baseline, and then after 6 weeks (midpoint), and then at the endpoint (12 weeks). The analysis takes into account all three time points, and reports the average change between each of the three time points.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00595556
|United States, Connecticut|
|University of Connecticut Health Center|
|Farmington, Connecticut, United States, 06030|
|Principal Investigator:||Albert J. Arias, MD||UConn Health|